Pharmacology · Cholinergic Pharmacology
Phosphorylation, aging, the full toxidrome, antidote pharmacology, and carbamate comparison
Abbreviations: AChE = acetylcholinesterase · NMJ = neuromuscular junction · BBB = blood-brain barrier · 2-PAM = pralidoxime · GABA = gamma-aminobutyric acid · SLUDGE = salivation, lacrimation, urination, defecation, GI distress, emesis
Organophosphate Inhibition and the Aging Phenomenon
The Cholinergic Toxidrome — Three Components
Atropine addresses causes 2, 3, and 4 (muscarinic and CNS). Mechanical ventilation is the only intervention that addresses all four simultaneously.
The Antidote Triad — Three Targets, Three Drugs
Organophosphates vs. Carbamates — Key Differences
| Feature | Organophosphates | Carbamates |
|---|---|---|
| Mechanism | Phosphorylation of active site serine | Carbamylation of active site serine |
| Aging | Yes — adduct becomes permanently resistant to pralidoxime over time | No — carbamyl adduct spontaneously hydrolyzes (30–120 min half-life) |
| Enzyme Recovery | Only with pralidoxime (before aging) or synthesis of new enzyme | Spontaneous, without antidote |
| Pralidoxime | Indicated — give early and continue 24–48 hours | Not indicated — may be harmful; enzyme recovers on its own |
| Atropine | Required — titrate to secretion drying | Required — same titration principle; dose requirements typically lower |
| Clinical Course | Potentially prolonged; redistribution from tissue stores can cause relapse | Shorter and more self-limited; symptoms typically resolve in 6–24 hours |
| Toxidrome | Full cholinergic toxidrome | Full cholinergic toxidrome (identical presentation) |
Suggested References
| Author / Organization | Title | Source |
|---|---|---|
| Katzung BG (ed) | Basic and Clinical Pharmacology, 15th ed. | McGraw-Hill, 2021 |
| Brunton LL, Knollmann BC (eds) | Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed. | McGraw-Hill, 2023 |
| Colovic MB, Krstic DZ, Lazarevic-Pasti TD, et al | Acetylcholinesterase inhibitors: pharmacology and toxicology | Curr Neuropharmacol. 2013;11(3):315–335 |
| Eddleston M, Buckley NA, Eyer P, Dawson AH | Management of acute organophosphorus pesticide poisoning | Lancet. 2008;371(9612):597–607 |
| Karalliedde L, Senanayake N | Organophosphorus insecticide poisoning | Br J Anaesth. 1989;63(6):736–750 |
| Jokanovic M | Medical treatment of acute poisoning with organophosphorus and carbamate pesticides | Toxicol Lett. 2009;190(2):107–115 |
| Holstege CP, Kirk M, Sidell FR | Chemical warfare: nerve agent poisoning | Crit Care Clin. 1997;13(4):923–942 |
| Eddleston M, Eyer P, Worek F, et al | Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study | Lancet. 2005;366(9495):1452–1459 |
| Treiman DM | GABAergic mechanisms in epilepsy | Epilepsia. 2001;42(Suppl 3):8–12 |
| Reigart JR, Roberts JR | Recognition and Management of Pesticide Poisonings, 6th ed. | US Environmental Protection Agency, 2013 |
| Worek F, Thiermann H, Wille T | Oximes in organophosphate poisoning: 60 years of hope and despair | Chem Biol Interact. 2016;259(Pt B):93–98 |
| Thiermann H, Worek F, Kehe K | Limitations and challenges in treatment of acute chemical warfare agent poisoning | Chem Biol Interact. 2013;206(3):435–443 |
| Bradberry SM, Cage SA, Proudfoot AT, Vale JA | Poisoning due to pyrethroids | Toxicol Rev. 2005;24(2):93–106 |
| Munoz-Quezada MT, Lucero BA, Iglesias VP, et al | Chronic exposure to organophosphate pesticides and neuropsychological functioning in farm workers | Int J Occup Environ Health. 2016;22(1):68–79 |